Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma
Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This is a phase II study of induction chemotherapy (capecitabine, oxaliplatin and cetuximab
(erbitux)) followed by capecitabine, oxaliplatin, cetuximab and radiotherapy followed by
surgery followed by adjuvant capecitabine, oxaliplatin and cetuximab for locally advanced
resectable rectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania